Terms ending in 2026
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,951,771 | Activin-Actriia Antagonists and Uses for Promoting Bone Growth In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 8,067,360 | A Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 8,128,933 | A Method of Promoting Bone Growth by an Anti-Activin B Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 8,486,403 | A Method of Promoting Bone Growth by an Anti-Activin a Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 8,629,109 | Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Low confidence | Acceleron Pharma Inc. | In force | Low confidence | |
| US 9,163,075 | AN ISOLATED POLYNUCLEOTIDE THAT ENCODES AN ActRIIa-Fc FUSION POLYPEPTIDE In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 9,480,742 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 9,572,865 | Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 10,071,135 | A Method of Identifying an Agent That Promotes Bone Growth or Increases Bone Density In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,239,940 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| 3 more term ends in 2026 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13, all of them expiring within the 18 months from Nov 19, 2026.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.